Next, how should pharmaceutical companies highlight their encirclement?

As a "rigid demand", medicine is an industry with long-term steady growth
.
Although some companies in the sector have been affected by policy adjustments such as centralized procurement in the short term, there are also many companies that have benefited from the resonance of the industry cycle and the era cycle
.
In the long run, with the deepening of domestic aging, the increase in medical and health investment, and the continuous improvement of health consumption, the prospects of the pharmaceutical industry are generally optimistic in the industry
.
So, after the A-share medical and biological sector continues to pull back, how can companies break out of the siege? Invesco Great Wall Fund Manager pointed out that the general direction of the pharmaceutical industry policy has been very clear, and companies with continuous innovation capabilities and internationalization are expected to stand out
.
Among them, in terms of innovation, the ability of the company's pipeline to continue to iterate is very important; in terms of internationalization, the domestic market may not be the source of excess profits in the future, but the scale advantage of the formation of the domestic market and the cost efficiency advantage of R&D are sufficient for these companies Gain international competitiveness
.
Innovation can be said to be one of the generally optimistic directions in the industry
.
At present, a batch of innovative drugs and devices in China have gradually been approved for marketing, ushering in new growth opportunities
.
The industry predicts that the focus of investment in pharmaceutical stocks in the next 2-3 years may be on innovative drugs and devices and the scientific research services that serve them
.
Pharmaceutical or medical device companies with core technologies and strong innovation capabilities will have opportunities .
Internationalization is a layout opportunity for pharmaceutical companies under the influence of medical insurance control fees and centralized procurement policies
.
Domestic giants have been actively participating in the layout of international certification in recent years, and the industry believes that pharmaceutical companies with good technology and international competition can be tapped
.
Everbright Securities also pointed out that the current national centralized drug procurement has reached the fifth round, and the national centralized procurement in the field of medical devices is also in the process of advancing
.
On the whole, marketization and internationalization are the trends of the domestic pharmaceutical industry, and reform is to promote better allocation of resources and improve overall efficiency
.
The agency's analysis pointed out that a new round of reforms in the pharmaceutical industry is expected to start, and subsequent policies to improve the epidemic prevention system and target the pharmaceutical industry will be introduced one after another.
Many sub-sectors will usher in a period of development opportunities, such as Internet medicine, medical protection, medical equipment, and vaccines.
, blood products, antiviral drugs, CRO, ICL like
.
In addition, this year CDE also launched the "Clinical Value-Oriented Anti-tumor Drug Clinical Trial R&D Guidelines" to further standardize R&D principles and strive for true innovation
.
The agency believes that, after the policy reform of Biomedical and Biology to encourage true innovation, the industry has gradually entered an innovation harvest period, and the strength of local innovative companies has gradually revealed, and innovative drugs have become the mainstream of drug development
.
With the rise of local innovation forces, the wave of domestic substitution and internationalization is coming
.
In the field of domestic substitution, policy support for domestic medical devices has continued to increase in recent years, and there is ample room for import substitution in this segment
.
It is understood that since 2016, the Chinese Society for Medical Equipment has released 7 batches of excellent domestic medical equipment product catalogs, covering multiple categories such as color Doppler ultrasound, CT, and monitors.
Among them, Mindray Medical, Kaili Medical, United Imaging Medical, Wanfu A variety of products from many companies such as biotechnology entered the catalog
.
In addition to policy support, in the context of increasing pressure on medical insurance control fees, hospitals will also consider cost-effective when purchasing medical devices, and domestic medical devices with outstanding cost-effectiveness have attracted more attention
.